TABLE 1.
Clinical characteristics of patients
| Age (years) | n | 51 |
|---|---|---|
| Mean | 60.8 | |
| SD | 9.7 | |
| Min | 39 | |
| Max | 81 | |
| Sex, n (%) | Male | 25 (49.0) |
| Female | 26 (51.0) | |
| Smoking status, n (%) | Yes | 14 (27.5) |
| No | 37 (72.5) | |
| PS, n (%) | 0 | 32 (62.8) |
| 1 | 17 (33.3) | |
| 2 | 2 (3.9) | |
| Disease stage, n (%) | IV | 48 (94.1) |
| IIIb | 3 (5.9) | |
| Malignant pleural effusion, n (%) | Yes | 10 (19.6) |
| No | 41 (80.4) | |
| Brain metastasis, n (%) | Yes | 8 (15.7) |
| No | 43 (84.3) | |
| Bone metastases, n (%) | Yes | 28 (54.9) |
| No | 23 (45.1) | |
| Tumor size (cm) | Median | 3.6 |
| Min | 0.7 | |
| Max | 12.2 | |
| CEA, n (%) | ≤5.00 ng/ml | 12 (23.5) |
| >5.00 ng/ml | 39 (76.5) | |
| First‐line treatment of EGFR‐TKIs, n (%) | Osimertinib | 5 (9.8) |
| Gefitinib | 12 (23.5) | |
| Icotinib | 4 (7.8) | |
| Posterior treatment of EGFR‐TKIs, n (%) | Osimertinib | 30 (58.8) |
Abbreviations: CEA, carcinoembryonic antigen; EGFR‐TKIs, epidermal growth factor receptor‐tyrosine kinase inhibitors; PS, performance status.